ANN ARBOR, Mich., Nov. 8, 2011 /PRNewswire/ -- Adeona
Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative
medicines for serious central nervous system diseases, announced
today that George J. Brewer, M.D.,
the Company's Senior Vice President of Research & Development,
will be a featured speaker at the 52nd Annual Meeting of the
American College of Nutrition to be held in Morristown, New Jersey, on November 16-19, 2011. Dr. Brewer is the Morton S.
and Henrietta Sellner Emeritus Professor of Human Genetics and
Internal Medicine at the University of
Michigan.
Dr. Brewer will moderate the "Important Developments with Trace
Elements" symposium with Ananda S.
Prasad, M.D., Ph.D., a Distinguished Professor of Internal
Medicine at Wayne State University
School of Medicine and an Adeona Scientific Advisory Board member.
During this symposium, Dr. Brewer will discuss the role of zinc
deficiency and copper toxicity on cognitive loss and their
contributions to the current epidemic of Alzheimer's disease.
Adeona also announced that, Diana
Pollock, M.D., Lead Principal Investigator of the Company's
clinical study that evaluated reaZin™ in
Alzheimer's disease patients at Morton Plant Neuroscience Institute
on the campus of Morton Plant Hospital, will present top-line
results that demonstrated, on average, that the cognitive function
(as measured by three standardized cognitive tests) of the
Alzheimer's patients managed with reaZin remained relatively
stable over six months, while the placebo group showed
deterioration. In addition, Dr. Pollock will present the
age-related subgroup analysis that showed dosing-compliant
Alzheimer's patients age 70 and over demonstrated statistically
significant improvements in two of the three cognitive scoring
measurements in the reaZin treatment group compared to the
placebo group. Adeona's product candidate, reaZin (zinc
cysteine), is being developed as a medical food for the dietary
management of zinc deficiency associated with Alzheimer's
disease.
About the American College of Nutrition (ACN)
The mission of the ACN is to improve the quality of nutrition
care by enhancing nutrition education for physicians. An integral
part of ACN's education activities is providing opportunities to
fill in the gaps in the current medical school curriculum as well
as ongoing post-graduate training. The goal of this training is to
enhance nutrition and metabolism knowledge and to promote the
application of such knowledge in clinical practice for the
prevention and treatment of disease. For more information about
ACN, please visit the website at
www.americancollegeofnutrition.org.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company focused on developing
innovative medicines for the treatment of serious central nervous
system diseases. The Company's strategy is to license product
candidates that have demonstrated a certain level of clinical
efficacy and develop them to a stage that results in a significant
commercial collaboration. Adeona is developing, or has partnered
the development of, drug product candidates to treat multiple
sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and
Alzheimer's disease. The Company is currently preparing to make the
following products commercially available: reaZin™, a
prescription medical food for the dietary management of zinc
deficiency associated with Alzheimer's disease, and
wellZin™, a homeopathic over-the-counter medicine for
reducing the duration and symptoms of the common cold. Adeona also
operates Adeona Clinical Laboratory, a wholly owned clinical
reference laboratory that provides a broad array of chemistry and
microbiology diagnostic tests. For more information, please visit
Adeona's website at www.adeonapharma.com.
This release includes forward-looking statements on Adeona's
current expectations and projections about future events. In some
cases forward-looking statements can be identified by terminology
such as "may," "could," "potential," "expects," "anticipates,"
"intends," "plans," "believe," "estimates," and similar
expressions. These statements are based upon current beliefs,
expectations and assumptions and are subject to a number of risks
and uncertainties, many of which are difficult to predict and
include statements regarding the use of zinc as a potential dietary
management for cognitive deficits in Alzheimer's patients, the
limitations inherent in post-hoc interpretations of clinical study
results and our intent to further commercialize development of
reaZin as a medical food. The forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from those reflected in
Adeona's forward-looking statements include, among others, our
failure to successfully commercialize reaZin for the management of
Alzheimer's disease, the failure of reaZin to be accepted for
dietary management of Alzheimer's disease, and other factors
described in Adeona's report on Form 10-K for the year ended
December 31, 2010 and any
other filings with the SEC. The information in this release is
provided only as of the date of this release, and Adeona undertakes
no obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
SOURCE Adeona Pharmaceuticals, Inc.